AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 192 min read$CRSP

CRISPR Therapeutics AG (CRSP) Appoints A.J. Silver CFO as Prasad Departs

CRISPR Therapeutics AG announced CFO Raju Prasad's departure and A.J. Silver's promotion to CFO. The change is effective immediately, according to the company.

Original reporting
tradingview.com
Published Oct 19, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 19, 2026, 8:12 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
CRISPR Therapeutics AG (CRSP) Appoints A.J. Silver CFO as Prasad Departs — source image
Source · tradingview.com
Decision brief

The 30-second read

$CRSPNeutralLow
01

Why it matters

Executive turnover is a governance update that may affect investor confidence.

02

Market read

New CFO appointment provides fresh information for traders monitoring biotech leadership changes.

03

What to watch

Potential hidden restructuring plans or financing initiatives under the new CFO.

Relevance 7/10Novelty 7/10Timing: effective today

Background

CRISPR Therapeutics AG is a gene-editing biotech with ongoing clinical programs.

Company-level read

Ticker impact

$CRSPNeutralMedium confidence
Context

CFO Raju Prasad stepped down and A.J. Silver was appointed CFO effective today.

Expected impact

potential modest pressure as investors assess the new CFO.

Evidence & confidence

Executive changes are material but typically do not trigger large moves without additional guidance.

Market effects

Sector

May influence biotech sector sentiment on governance stability.

Regional

Limited to US-listed biotech investors.

Global

Low global impact beyond CRISPR Therapeutics.

Counterpoint

What could challenge this read

The CFO change could be a catalyst for upside if the new CFO accelerates capital strategy.

Key entities

  • company
    CRISPR Therapeutics AG

    Gene-editing biotech (ticker CRSP).

  • person
    A.J. Silver

    Appointed CFO.

Read at source← All news

StoryCRISPR Therapeutics appoints A.J. Silver as new CFO after Raju Prasad departs

Related articles

OCT 9
$CRSPMedAI 8/10

H.C. Wainwright reiterates Buy on CRISPR stock, $80 target

H.C. Wainwright reiterated a Buy rating and $80 price target for CRISPR Therapeutics (CRSP), citing potential upside from its current $50.44 share price. The stock has declined 9% over the past week. CRISPR will present Phase 1b data for CTX310 at the AHA conference, with analysts noting significant triglyceride reductions. The company's Fair Value is currently above its trading price, according to InvestingPro.

investing.com1 min
OCT 2
$CRSPMedAI 8/10

CRISPR Therapeutics to Present Clinical Data on Zugocabtagene Geleucel (Zugo-cel) in Autoimmune Disease at the American College of Rheumatology (ACR) Convergence 2026

CRISPR Therapeutics (CRSP) will present Phase 1 clinical data on its gene-edited CAR T cell therapy, zugocabtagene geleucel (zugo-cel), for autoimmune diseases at the ACR Convergence 2026. The presentation focuses on the therapy's safety and efficacy in treating refractory systemic sclerosis. CRISPR Therapeutics is a biopharmaceutical company developing gene-based medicines, with a pipeline spanning various diseases.

globenewswire.com1 min
SEP 26
$SNOWMed

Snowflake, Palo Alto, Dell, GameStop, Crispr Insider Shock

Insiders at Snowflake (SNOW), Palo Alto (PANW), Dell (DELL), GameStop (GME), and Crispr (CRSP) made notable trades. SNOW's CRO sold $253,951 in shares, PANW's director sold $7.5M, DELL saw multiple sales totaling $22.9M, GME's CEO bought $26.4M in shares, and CRSP's shareholder sold $780,934. These transactions may signal insider expectations.

tipranks.com2 min